{"id":4066,"date":"2026-11-04T09:00:00","date_gmt":"2026-11-04T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4066"},"modified":"2026-11-04T21:49:26","modified_gmt":"2026-11-05T01:49:26","slug":"direct-hbb-correction-shows-early-sickle-cell-clinical-signal","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4066","title":{"rendered":"Direct HBB Correction Shows Early Sickle Cell Clinical Signal"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Kamau Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Interim Phase 1\/2 data disclosure (ASH abstract)<\/p>\n

Modality<\/strong><\/p>\n

Autologous HSC gene editing (homology-directed repair)<\/p>\n

Asset<\/strong><\/p>\n

Nula-cel<\/p>\n

Target<\/strong><\/p>\n

HBB E6V mutation<\/p>\n

Disease Area<\/strong><\/p>\n

Sickle cell disease<\/p>\n

Summary<\/h4>\n

Kamau Therapeutics disclosed November 4 interim Phase 1\/2 RESTORE data for three people with severe sickle cell disease given a revised nula-cel manufacturing process. Two have more than six months of follow-up with predominant adult hemoglobin. The sample is too small to establish durable clinical benefit or comparative advantage.<\/p>\n

All three patients became transfusion independent before discharge and none had a reported post-infusion vaso-occlusive event to date. Neutrophil engraftment occurred at a median 21 days. At 12 and eight months in the two longer-followed patients, total hemoglobin was 10.2 and 11.1 g\/dL, HbS 17.6% and 19.1%, and HbA 76.8% and 66.8%. Bone marrow homology-directed repair allele frequency stabilized near 20%, while drug-product editing was 32\u201338%. The disclosure says no serious adverse event was related to the product or editing procedure; busulfan and transplant toxicity remain relevant.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> precise repair of the HBB sickle mutation in engrafting HSCs can restore physiologic adult hemoglobin production. Stable marrow editing and the two HbA-dominant profiles support this. Counterargument: these are only two patients beyond six months, and erythroid selection may amplify blood-cell benefit relative to stem-cell correction.<\/p>\n

Interpretation B:<\/strong> the optimized process may be difficult to reproduce at scale, even if the first patients respond. Three successful products and a median one apheresis cycle argue for feasibility, but product release, long-term clone tracking and multisite consistency are unavailable. Larger cohorts, organ outcomes, off-target and on-target structural variant monitoring, graft durability, and direct comparisons of treatment burden would test clinical differentiation.<\/p>\n

Company and Product Background<\/h4>\n

Kamau develops nula-cel, autologous CD34-positive hematopoietic stem cells edited by homology-directed repair to correct the HBB E6V mutation. Sickle cell disease results from polymerization of mutant hemoglobin S, causing hemolysis and vaso-occlusion. The procedure requires myeloablative busulfan conditioning.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • These are disclosed ASH abstract results, not the full December 14 presentation or a peer-reviewed paper.<\/li>\n
  • The prior V1 patient with four-year follow-up is context, not part of the three-person V2 cohort.<\/li>\n
  • No comparison with HbF-induction gene-edited products is justified from this series.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Direct correction is now supported by an early human engraftment and hemoglobin signal. Replication and genomic safety over years are the decisive hurdles.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: cautiously positive for early pharmacodynamic effect; uncertain for long-term patient benefit. Confidence in Facts: moderate for a company disclosure of abstract data. Confidence in Interpretation: low-moderate due to n=3 and limited follow-up.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Kamau Therapeutics disclosed November 4 interim Phase 1\/2 RESTORE data for three people with severe sickle cell disease given a revised nula-cel manufacturing process. Two have more than six months of follow-up with predominant…<\/p>\n","protected":false},"author":1,"featured_media":4078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1359,1360,45],"class_list":["post-4066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-kamau-therapeutics","tag-nula-cel","tag-sickle-cell-disease"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4066"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4066\/revisions"}],"predecessor-version":[{"id":4084,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4066\/revisions\/4084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4078"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}